Adaptive immune response that restrains ALV

To determine the underlying mechanism within tumor-specific TMV cells that eliminates solid tumors with antigen heterogeneity, we used RNA-seq to analyze the global RNA expression of tumors Overall design: B16 cells were s.c. injected both flanks of the mice. Indicated treatments were administrated on day 7 when tumors reached ~7×6 mm. Adjuvant CTX (i.p.) was administered to mice one day before ACT. In group 3, free MV was intratumorally injected only into the left tumors [refers to 'MV (L. i.t.)'], and right tumors did not receive intratumorally injection [refers to 'remote tumor (no MV)']. Tumor tissues (~100 mg/mice, 12 days after ACT) were harvested. Total RNA was extracted from the tumor tissues for RNA-Seq (n=2).